Women of color are disproportionally affected by myositis diseases



Myositis is an inflammatory disease of the muscles that can cause severe disability. Symptoms include falling, trouble climbing stairs, difficulty raising arms over the head, and unusual rashes. In adults, certain forms of myositis affect women of color more than Caucasians.



For those with darker skin the rash of dermatomyositis may not be as easy to identify as it is on lighter skin.

African American myositis patients have higher frequencies of certain markers of more severe disease (antisynthetase syndrome and necrotizing myopathy) than European-American myositis patients.⁴

African Americans with ILD are younger at diagnosis.⁶

Creatine kinase levels (a measure of disease severity) were found to be significantly higher in African Americans compared to Caucasians.³ In adults, DM, PM, and NM affect more African Americans than Caucasians. ^{1, 2}

African American myositis patients with a complication called antisynthetase syndrome have more severe lung disease. ⁵

DISEASE ABBREVIATIONS & KEY TERMS

- DM dermatomyositis
- **ILD** interstitial lung disease
- JDM juvenile dermatomyositis
- **NM** necrotizing myopathy
- **PM** polymyositis

Nonwhite women are twice as likely to die than others with myositis, and they are four times more likely to die than white men with the disease.⁷



Nonwhite DM patients have greater lengths of stay and higher costs of care when they are hospitalized.⁸



Mortality rates from DM and PM are highest among women of color.⁷

In the childbearing years (ages 15-34), mortality in nonwhite women with myositis is 3.5 times greater than in Caucasian women with the disease. 7

African American children with JDM have an increased risk of developing calcinosis, a painful accumulation of calcium under the skin.⁹

Nonwhite women with multiple chronic conditions have the highest rates of hospitalization for dermatomyositis.⁸

Nonwhite women die at a younger age than others with DM and PM.⁷



While these statistics show the disproportionate burden of myositis on women of color, you are not alone! TMA is here for you with support and resources.

Sources

- Gaubitz, M. (2006). Epidemiology of connective tissue disorders. Rheumatology, 45(Suppl 3); iii3-iii4. doi:10.1093/rheumatology/kel282.
 Smoyer-Tomic, K.E., et al. 2012. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskeletal Disorders, 13(103). doi:10.1186/1471-2474-13-103.
- 3. Schiopu et al. 2012. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: Effect of corticosteroids, methotrexate, and azathioprine. Arthritis Research & Therapy,14(R22). doi:10.1186/ar3704.
- 4. Johnson C., et al. 2014. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respiratory Medicine, 108(10); 1542-1548. doi:10.1016/ j.rmed.2014.09.003.
- 5. Pinal-Fernandez, lago, et al. (2017). "A Longitudinal Cohort Study of the Anti-Synthetase Syndrome: Increased Severity of Interstitial Lung Disease in Black Patients and Patients with Anti-PL7 and Anti-PL12 Autoantibodies." Rheumatology, 56(6); 999-1007. doi:10.1093/rheumatology/kex021.
- 6. Adegunsoye, Ayodeji, et al. (2018). African-American race and mortality in interstitial lung disease: A multicentre propensity-matched analysis. European Respiratory Journal, 51(6). doi:10.1183/13993003.00255-2018.
- 7. Hochberg, Marc C., et al. 1983. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis & Rheumatism, 26(12); 1465-1471. doi:10.1002/art.1780261208.
- 8. Kwa, Michael C., et al. 2017. Predictors of hospitalization, length of stay, and cost of care among adults with dermatomyositis in the United States. Arthritis Care & Research, 69(9);1391-1399. doi:10.1002/acr.23190.
- 9. Hoeltzel, Mark F, et al. 2012. Race is a risk factor for calcinosis in patients with JDM: Early results from the CARRAnet registry study. Pediatric Rheumatology, 10(Suppl 1). doi:10.1186/1546-0096-10-s1-a65.

Sponsored by Mallinckrodt Pharmaceuticals